Abstract:Proteolysis targeting chimera (PROTAC) degraders are typically bifunctional with one moiety of an E3 ligase ligand connected to one target protein ligand via a linker. While augmented valency has been shown with trivalent PROTACs targeting two binding sites within a given target protein, or used to recruit two different targets, the possibility of recruiting two different E3 ligases within the same compound has not been demonstrated. Here we present dual-ligase recruitment as a strategy to enhance targeted protein degradation. We designed heterotrivalent PROTACs composed of a CRBN, VHL and BET targeting ligand, separately tethered via a branched trifunctional linker. Structure-activity relationships of 12 analogues qualifies AB3067 as the most potent and fastest degrader of BET proteins, with minimal E3 ligase cross-degradation. Comparative kinetic analyses in wild-type and ligase single and double knockout cell lines revealed that protein ubiquitination and degradation induced by AB3067 was contributed by both CRBN and VHL in an additive fashion. We further expand the scope of the dual-ligase approach by developing a hetero-trivalent CRBN/VHL-based BromoTag degrader and a tetravalent PROTAC comprising of two BET ligand moieties. In summary, we provide proof-of-concept for dual-E3 ligase recruitment as a strategy to boost degradation fitness by recruiting two E3 ligases with a single degrader molecule. This approach could potentially delay the outset of resistance mechanisms involving loss of E3 ligase functionality.

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points

Targeted protein degradation: expanding the toolbox

E3 ligase ligand optimization of Clinical PROTACs

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Discovery of E3 Ligase Ligands for Target Protein Degradation

Current Advances of Small Molecule E3 Ligands for Proteolysis-Targeting Chimeras Design

Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Bivalent Ligands for Protein Degradation in Drug Discovery

Leveraging dual-ligase recruitment to enhance degradation via a heterotrivalent PROTAC

Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation

Computational Strategies for PROTAC Drug Discovery

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Recent Advances in PROTACs for Drug Targeted Protein Research